RXRX RECURSION PHARMACEUTICALS, INC.
Nasdaq · SEC CIK 1601830 · EDGAR
- Bought, last 12 months
- $0 0 purchases by 0 insiders
- Sold, last 12 months
- $8.93M 36 sales by 5 insiders
- Filings on record
- 457 since 2021-07-06, latest 2026-09-16 17:52
BoughtSold
Most active insiders, 12 months
| Insider | Title | Bought | Sold |
|---|---|---|---|
| Borgeson Blake | Dir | — | $4.10M |
| Gibson Christopher | Dir | — | $3.84M |
| Khan Najat | Chief R, D Commercial Off, Dir | — | $806.7K |
| Taylor Ben R | CFO | — | $157.7K |
| Bumpus Namandje | Dir | — | $28.1K |
| Michor Franziska | Dir | — | — |
| Hallett David | CSO | — | — |
| Dar Zavain | Dir | — | — |
| Li Dean Y | Dir | — | — |
| Sun Elaine D | Dir | — | — |
Transactions 743
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-10-03 | 2025-10-01 | RXRX | Li Dean Y | Dir | A - Grant | $0.00 | +1,961 | 1.24M | +0.2% | $0 | |
| 2025-10-03 | 2025-10-01 | RXRX | Dar Zavain | Dir | A - Grant | $0.00 | +2,941 | 138.8K | +2% | $0 | |
| D | 2025-09-26 | 2025-09-25 | RXRX | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +100.0K | 1.05M | +10% | $0 |
| D | 2025-09-26 | 2025-09-25 | RXRX | Gibson Christopher | CEO, Dir | S - Sale | $4.76 | -100.0K | 954.2K | -9% | -$476.0K |
| 2025-09-17 | 2025-09-15 | RXRX | Taylor Ben R | CFO | F - Tax | $4.83 | -7,057 | 804.2K | -0.9% | -$34.1K | |
| D | 2025-09-12 | 2025-09-10 | RXRX | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +120.0K | 1.07M | +13% | $0 |
| D | 2025-09-12 | 2025-09-10 | RXRX | Gibson Christopher | CEO, Dir | G - Gift | $0.00 | -20.0K | 954.2K | -2% | $0 |
| D | 2025-09-12 | 2025-09-10 | RXRX | Gibson Christopher | CEO, Dir | S - Sale | $4.71 | -100.0K | 974.2K | -9% | -$471.0K |
| D | 2025-08-28 | 2025-08-26 | RXRX | Gibson Christopher | CEO, Dir | S - Sale | $4.84 | -100.0K | 954.2K | -9% | -$484.0K |
| D | 2025-08-28 | 2025-08-26 | RXRX | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +100.0K | 1.05M | +10% | $0 |
| 2025-08-19 | 2025-08-15 | RXRX | Gibson Christopher | CEO, Dir | F - Tax | $5.64 | -40.4K | 954.2K | -4% | -$227.8K | |
| 2025-08-19 | 2025-08-15 | RXRX | Taylor Ben R | CFO | F - Tax | $5.64 | -11.9K | 811.2K | -1% | -$67.2K | |
| 2025-08-19 | 2025-08-15 | RXRX | Khan Najat | Chief R, D Commercial Off, Dir | F - Tax | $5.64 | -3,789 | 704.8K | -0.5% | -$21.4K | |
| 2025-08-19 | 2025-08-18 | RXRX | Khan Najat | Chief R, D Commercial Off, Dir | S - Sale | $5.52 | -36.6K | 668.2K | -5% | -$202.0K | |
| D | 2025-08-13 | 2025-08-11 | RXRX | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +423.7K | 1.50M | +39% | $0 |
| D | 2025-08-13 | 2025-08-11 | RXRX | Gibson Christopher | CEO, Dir | S - Sale | $5.28 | -500.3K | 1.00M | -33% | -$2.64M |
| D | 2025-08-13 | 2025-08-11 | RXRX | Gibson Christopher | CEO, Dir | G - Gift | $0.00 | -10.0K | 994.6K | -1.0% | $0 |
| DMI | 2025-08-13 | 2025-08-11 | RXRX | Gibson Christopher | CEO, Dir | S - Sale | $5.28 | -117.9K | 0 | -100% | -$622.4K |
| DMI | 2025-08-13 | 2025-08-11 | RXRX | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +117.9K | 17.9K | New | $0 |
| 2025-07-03 | 2025-07-01 | RXRX | Li Dean Y | Dir | A - Grant | $0.00 | +1,949 | 1.24M | +0.2% | $0 | |
| 2025-07-03 | 2025-07-01 | RXRX | Dar Zavain | Dir | A - Grant | $0.00 | +2,924 | 135.8K | +2% | $0 | |
| D | 2025-06-23 | 2025-06-18 | RXRX | HERSHBERG ROBERT | Dir | A - Grant | $0.00 | +22.0K | 73.7K | +43% | $0 |
| D | 2025-06-23 | 2025-06-18 | RXRX | Michor Franziska | Dir | A - Grant | $0.00 | +22.0K | 127.1K | +21% | $0 |
| D | 2025-06-23 | 2025-06-18 | RXRX | Dar Zavain | Dir | A - Grant | $0.00 | +22.0K | 132.9K | +20% | $0 |
| D | 2025-06-23 | 2025-06-18 | RXRX | Borgeson Blake | Dir | A - Grant | $0.00 | +22.0K | 7.09M | +0.3% | $0 |
| D | 2025-06-23 | 2025-06-18 | RXRX | Bumpus Namandje | Dir | A - Grant | $0.00 | +11.0K | 47.6K | +30% | $0 |
| D | 2025-06-23 | 2025-06-18 | RXRX | Sun Elaine D | Dir | A - Grant | $0.00 | +11.0K | 47.6K | +30% | $0 |
| D | 2025-06-23 | 2025-06-18 | RXRX | Li Dean Y | Dir | A - Grant | $0.00 | +22.0K | 1.23M | +2% | $0 |
| 2025-06-18 | 2025-06-16 | RXRX | Taylor Ben R | CFO | F - Tax | $4.92 | -7,057 | 823.1K | -0.9% | -$34.7K | |
| 2025-05-19 | 2025-05-15 | RXRX | Taylor Ben R | CFO | F - Tax | $4.25 | -11.9K | 830.2K | -1% | -$50.6K | |
| 2025-05-19 | 2025-05-15 | RXRX | Gibson Christopher | CEO, Dir | F - Tax | $4.25 | -36.2K | 1.08M | -3% | -$153.8K | |
| 2025-05-19 | 2025-05-15 | RXRX | Khan Najat | Chief R, D Commercial Off, Dir | F - Tax | $4.25 | -3,796 | 708.6K | -0.5% | -$16.1K | |
| 2025-04-03 | 2025-04-01 | RXRX | Dar Zavain | Dir | A - Grant | $0.00 | +2,745 | 110.9K | +3% | $0 | |
| 2025-04-03 | 2025-04-01 | RXRX | Li Dean Y | Dir | A - Grant | $0.00 | +2,268 | 79.6K | +3% | $0 | |
| 2025-04-03 | 2025-04-01 | RXRX | Taylor Ben R | CFO | F - Tax | $5.10 | -26.6K | 842.1K | -3% | -$135.5K | |
| 2025-03-28 | 2025-03-27 | RXRX | Gibson Christopher | CEO, Dir | S - Sale | $6.04 | -138.6K | 1.12M | -11% | -$837.0K | |
| D | 2025-03-19 | 2025-03-17 | RXRX | Sun Elaine D | Dir | A - Grant | $0.00 | +36.5K | 36.5K | New | $0 |
| 2025-03-19 | 2025-03-17 | RXRX | Taylor Ben R | CFO | F - Tax | $6.84 | -7,057 | 868.7K | -0.8% | -$48.3K | |
| D | 2025-03-19 | 2025-03-17 | RXRX | Bumpus Namandje | Dir | A - Grant | $0.00 | +36.5K | 36.5K | New | $0 |
| DM | 2025-03-07 | 2025-03-05+ | RXRX | Gibson Christopher | CEO, Dir | S - Sale | $6.47 | -40.0K | 1.26M | -3% | -$259.0K |
| DM | 2025-03-07 | 2025-03-05+ | RXRX | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +40.0K | 1.28M | +3% | $0 |
| 2025-02-20 | 2025-02-18 | RXRX | Gibson Christopher | CEO, Dir | F - Tax | $10.64 | -17.1K | 1.26M | -1% | -$182.3K | |
| 2025-02-20 | 2025-02-18 | RXRX | Taylor Ben R | CFO | F - Tax | $10.64 | -10.9K | 875.7K | -1% | -$115.8K | |
| DM | 2025-02-07 | 2025-02-05+ | RXRX | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +40.0K | 1.29M | +3% | $0 |
| DM | 2025-02-07 | 2025-02-05+ | RXRX | Gibson Christopher | CEO, Dir | S - Sale | $7.90 | -40.0K | 1.27M | -3% | -$316.0K |
| D | 2025-02-05 | 2025-02-03 | RXRX | Khan Najat | Chief R, D Commercial Off, Dir | F - Tax | $7.25 | -2,753 | 712.4K | -0.4% | -$20.0K |
| DM | 2025-02-05 | 2025-02-03 | RXRX | Khan Najat | Chief R, D Commercial Off, Dir | A - Grant | $0.00 | +218.2K | 715.1K | +44% | $0 |
| D | 2025-02-05 | 2025-02-03 | RXRX | Taylor Ben R | CFO | F - Tax | $7.25 | -6,544 | 886.6K | -0.7% | -$47.4K |
| DM | 2025-02-05 | 2025-02-03 | RXRX | Taylor Ben R | CFO | A - Grant | $0.00 | +48.9K | 879.2K | +6% | $0 |
| DM | 2025-02-05 | 2025-02-03 | RXRX | Gibson Christopher | CEO, Dir | A - Grant | $0.00 | +542.1K | 1.28M | +74% | $0 |
| D | 2025-02-05 | 2025-02-03 | RXRX | Gibson Christopher | CEO, Dir | F - Tax | $7.25 | -5,569 | 1.27M | -0.4% | -$40.4K |
| DM | 2025-01-13 | 2025-01-08+ | RXRX | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +40.0K | 756.6K | +6% | $0 |
| DM | 2025-01-13 | 2025-01-08+ | RXRX | Gibson Christopher | CEO, Dir | S - Sale | $7.18 | -40.0K | 736.6K | -5% | -$287.2K |
| 2025-01-06 | 2025-01-02 | RXRX | Li Dean Y | Dir | A - Grant | $0.00 | +1,647 | 77.3K | +2% | $0 | |
| 2025-01-06 | 2025-01-02 | RXRX | Dar Zavain | Dir | A - Grant | $0.00 | +1,907 | 108.1K | +2% | $0 | |
| 2025-01-06 | 2025-01-02 | RXRX | Borgeson Blake | Dir | A - Grant | $0.00 | +1,734 | 7.07M | +0.0% | $0 | |
| D | 2024-12-20 | 2024-12-19 | RXRX | Taylor Ben R | CFO | A - Grant | $0.00 | +370.3K | 844.2K | +78% | $0 |
| M | 2024-12-18 | 2024-12-16+ | RXRX | Taylor Ben R | CFO | F - Tax | $6.32 | -22.7K | 480.9K | -5% | -$143.7K |
| DM | 2024-12-06 | 2024-12-04+ | RXRX | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +40.0K | 756.6K | +6% | $0 |
| DM | 2024-12-06 | 2024-12-04+ | RXRX | Gibson Christopher | CEO, Dir | S - Sale | $7.14 | -40.0K | 736.6K | -5% | -$285.6K |
| DM | 2024-11-22 | 2024-11-20 | RXRX | Michor Franziska | Dir | A - Grant | $0.00 | +105.0K | 105.0K | New | $0 |
| 2024-11-19 | 2024-11-15 | RXRX | Mauro David J | Chief Medical Off | F - Tax | $6.18 | -4,187 | 225.4K | -2% | -$25.9K | |
| 2024-11-19 | 2024-11-15 | RXRX | Secora Michael | CFO | F - Tax | $6.18 | -11.9K | 1.49M | -0.8% | -$73.8K | |
| 2024-11-19 | 2024-11-15 | RXRX | Marriott Tina | Pres, COO | F - Tax | $6.18 | -14.3K | 506.9K | -3% | -$88.3K | |
| 2024-11-19 | 2024-11-15 | RXRX | Gibson Christopher | CEO, Dir | F - Tax | $6.18 | -26.0K | 736.6K | -3% | -$160.8K | |
| DM | 2024-11-15 | 2024-11-13+ | RXRX | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +40.0K | 782.7K | +5% | $0 |
| DM | 2024-11-15 | 2024-11-13+ | RXRX | Gibson Christopher | CEO, Dir | S - Sale | $7.54 | -40.0K | 762.7K | -5% | -$301.8K |
| DM | 2024-11-14 | 2024-11-12+ | RXRX | Secora Michael | CFO | M - OptEx | $2.22 | +78.8K | 1.51M | +5% | +$174.8K |
| DM | 2024-11-14 | 2024-11-12+ | RXRX | Secora Michael | CFO | S - Sale+OE | $7.65 | -30.0K | 1.48M | -2% | -$229.5K |
| 2024-11-14 | 2024-11-12 | RXRX | Borgeson Blake | Dir | S - Sale | $7.64 | -11.4K | 7.07M | -0.2% | -$87.5K | |
| 2024-10-31 | 2024-10-29 | RXRX | Borgeson Blake | Dir | S - Sale | $6.72 | -11.4K | 7.08M | -0.2% | -$76.9K | |
| D | 2024-10-28 | 2024-10-24 | RXRX | Marriott Tina | Pres, COO | S - Sale+OE | $6.31 | -6,000 | 521.1K | -1% | -$37.9K |
| D | 2024-10-28 | 2024-10-24 | RXRX | Marriott Tina | Pres, COO | M - OptEx | $1.06 | +6,000 | 527.1K | +1% | +$6,360 |
| 2024-10-17 | 2024-10-15 | RXRX | Borgeson Blake | Dir | S - Sale | $6.67 | -11.4K | 7.09M | -0.2% | -$76.4K | |
| DM | 2024-10-10 | 2024-10-08+ | RXRX | Secora Michael | CFO | M - OptEx | $2.22 | +78.8K | 1.44M | +6% | +$174.8K |
| DM | 2024-10-10 | 2024-10-08+ | RXRX | Secora Michael | CFO | S - Sale+OE | $6.34 | -30.0K | 1.45M | -2% | -$190.2K |
| 2024-10-04 | 2024-10-01 | RXRX | Dar Zavain | Dir | A - Grant | $0.00 | +2,229 | 106.2K | +2% | $0 | |
| DM | 2024-10-04 | 2024-10-02+ | RXRX | Gibson Christopher | CEO, Dir | S - Sale | $6.12 | -40.0K | 762.7K | -5% | -$244.8K |
| DM | 2024-10-04 | 2024-10-02+ | RXRX | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +40.0K | 782.7K | +5% | $0 |
| 2024-10-04 | 2024-10-01 | RXRX | Borgeson Blake | Dir | A - Grant | $0.00 | +2,026 | 7.10M | +0.0% | $0 | |
| 2024-10-04 | 2024-10-01 | RXRX | Li Dean Y | Dir | A - Grant | $0.00 | +1,925 | 75.7K | +3% | $0 | |
| 2024-10-03 | 2024-10-01 | RXRX | Borgeson Blake | Dir | S - Sale | $6.22 | -11.4K | 7.10M | -0.2% | -$71.2K | |
| D | 2024-09-30 | 2024-09-26 | RXRX | Marriott Tina | Pres, COO | S - Sale+OE | $7.00 | -6,000 | 521.1K | -1% | -$42.0K |
| D | 2024-09-30 | 2024-09-26 | RXRX | Marriott Tina | Pres, COO | M - OptEx | $1.06 | +6,000 | 527.1K | +1% | +$6,360 |
| 2024-09-19 | 2024-09-17 | RXRX | Borgeson Blake | Dir | S - Sale | $6.84 | -11.4K | 7.11M | -0.2% | -$78.3K | |
| DM | 2024-09-12 | 2024-09-10+ | RXRX | Secora Michael | CFO | S - Sale+OE | $6.25 | -30.0K | 1.38M | -2% | -$187.3K |
| DM | 2024-09-12 | 2024-09-10+ | RXRX | Secora Michael | CFO | M - OptEx | $2.22 | +78.8K | 1.39M | +6% | +$174.8K |
| DM | 2024-09-06 | 2024-09-04+ | RXRX | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +40.0K | 782.7K | +5% | $0 |
| DM | 2024-09-06 | 2024-09-04+ | RXRX | Gibson Christopher | CEO, Dir | S - Sale | $6.09 | -40.0K | 762.7K | -5% | -$243.6K |
| 2024-09-05 | 2024-09-03 | RXRX | Borgeson Blake | Dir | S - Sale | $6.27 | -11.4K | 7.12M | -0.2% | -$71.8K | |
| D | 2024-09-03 | 2024-08-29 | RXRX | Marriott Tina | Pres, COO | M - OptEx | $1.06 | +6,000 | 527.1K | +1% | +$6,360 |
| D | 2024-09-03 | 2024-08-29 | RXRX | Marriott Tina | Pres, COO | S - Sale+OE | $7.56 | -6,000 | 521.1K | -1% | -$45.4K |
| D | 2024-08-30 | 2024-08-30 | RXRX | Gibson Christopher | CEO, Dir | M - OptEx | $2.48 | +5,000 | 762.7K | +0.7% | +$12.4K |
| D | 2024-08-29 | 2024-08-29 | RXRX | Gibson Christopher | CEO, Dir | M - OptEx | $2.48 | +5,000 | 757.7K | +0.7% | +$12.4K |
| D | 2024-08-28 | 2024-08-28 | RXRX | Gibson Christopher | CEO, Dir | M - OptEx | $2.48 | +5,000 | 752.7K | +0.7% | +$12.4K |
| D | 2024-08-27 | 2024-08-27 | RXRX | Gibson Christopher | CEO, Dir | M - OptEx | $2.48 | +5,000 | 747.7K | +0.7% | +$12.4K |
| D | 2024-08-26 | 2024-08-26 | RXRX | Gibson Christopher | CEO, Dir | M - OptEx | $2.48 | +5,000 | 742.7K | +0.7% | +$12.4K |
| D | 2024-08-23 | 2024-08-23 | RXRX | Gibson Christopher | CEO, Dir | M - OptEx | $2.48 | +5,000 | 737.7K | +0.7% | +$12.4K |
| 2024-08-22 | 2024-08-20 | RXRX | Borgeson Blake | Dir | S - Sale | $7.12 | -11.4K | 7.13M | -0.2% | -$81.5K | |
| 2024-08-19 | 2024-08-15 | RXRX | Gibson Christopher | CEO, Dir | F - Tax | $6.69 | -26.1K | 732.7K | -3% | -$174.5K |
Purchase Sale Sale after option exercise All abbreviations